| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849911 | BRISTOL | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(6 years ago) | |
| US6087383 | BRISTOL | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(5 years ago) | |
| US8148374 | BRISTOL | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5849911 (Pediatric) | BRISTOL | Antivirally active heterocyclic azahexane derivatives |
Dec, 2017
(6 years ago) | |
|
US6087383 (Pediatric) | BRISTOL | Bisulfate salt of HIV protease inhibitor |
Jun, 2019
(4 years ago) | |
| US10039718 | BRISTOL | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
Evotaz is owned by Bristol.
Evotaz contains Atazanavir Sulfate; Cobicistat.
Evotaz has a total of 6 drug patents out of which 4 drug patents have expired.
Expired drug patents of Evotaz are:
- US5849911*PED
- US6087383*PED
- US5849911
- US6087383
Evotaz was authorised for market use on 29 January, 2015.
Evotaz is available in tablet;oral dosage forms.
Evotaz can be used as method for treating hiv-1 infection, treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.
Drug patent challenges can be filed against Evotaz from 27 August, 2016.
The generics of Evotaz are possible to be released after 06 October, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: Method for treating hiv-1 infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL
EVOTAZ family patents
